Literature DB >> 8455933

CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene.

N Ohtani-Fujita1, T Fujita, A Aoike, N E Osifchin, P D Robbins, T Sakai.   

Abstract

Cytosine methylation of CpG sites in the promoter region of eucaryotic genes is involved in the inactivation of expression of certain genes. Given that methylation can lead to reduced transcription, it is possible that expression of tumor-suppressor genes is also inactivated by hypermethylation, thereby contributing to the etiology of cancer. Recently we found five sporadic retinoblastoma tumors (16% of all unilateral cases) with hypermethylation of the 5' end of the retinoblastoma gene without detecting any structural abnormalities. However, it is unclear whether the promoter of the retinoblastoma gene is actually inactivated by its hypermethylation. Here we show that specific hypermethylation in the promoter region of the retinoblastoma gene reduces its expression to only 8% of the unmethylated control. Furthermore, we have found that two transcription factors important for the promoter activity, an activating transcription factor (ATF)-like factor and the retinoblastoma binding factor 1, do not bind when their recognition sequences are CpG methylated. These results in vitro strongly support the hypothesis that CpG methylation of the human tumor-suppressor gene can result in the inactivation of the gene and thus lead to oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8455933

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

1.  CpG methylation as a mechanism for the regulation of E2F activity.

Authors:  M R Campanero; M I Armstrong; E K Flemington
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Regulation of DNA methylation of Rasgrf1.

Authors:  Bong June Yoon; Herry Herman; Aimee Sikora; Laura T Smith; Christoph Plass; Paul D Soloway
Journal:  Nat Genet       Date:  2001-12-20       Impact factor: 38.330

3.  Sequence-specific transcriptional repression by an MBD2-interacting zinc finger protein MIZF.

Authors:  Masayuki Sekimata; Yoshimi Homma
Journal:  Nucleic Acids Res       Date:  2004-01-29       Impact factor: 16.971

4.  Epigenetics and assisted reproductive technology: a call for investigation.

Authors:  Emily L Niemitz; Andrew P Feinberg
Journal:  Am J Hum Genet       Date:  2004-02-27       Impact factor: 11.025

5.  Quantitative DNA methylation analysis: the promise of high-throughput epigenomic diagnostic testing in human neoplastic disease.

Authors:  William B Coleman; Ashley G Rivenbark
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

Review 6.  Epigenetic regulation of human retinoblastoma.

Authors:  Usha Singh; Manzoor Ahmad Malik; Sandeep Goswami; Swati Shukla; Jasbir Kaur
Journal:  Tumour Biol       Date:  2016-09-17

7.  Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma.

Authors:  Lauren E Hudson; Pia Mendoza; William H Hudson; Alison Ziesel; G Baker Hubbard; Jill Wells; Bhakti Dwivedi; Jeanne Kowalski; Sandra Seby; Viren Patel; Eldon Geisert; Charles Specht; Hans E Grossniklaus
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

8.  Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production.

Authors:  J A Mikovits; H A Young; P Vertino; J P Issa; P M Pitha; S Turcoski-Corrales; D D Taub; C L Petrow; S B Baylin; F W Ruscetti
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas.

Authors:  K Yoshiura; Y Kanai; A Ochiai; Y Shimoyama; T Sugimura; S Hirohashi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

Review 10.  Biomarkers in retinoblastoma.

Authors:  Jie Sun; Hui-Yu Xi; Qing Shao; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.